{"filing":{"accession_number":"0001801170-26-000137","cik":"0001801170","ticker":"CLOV","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"clov-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000137/clov-20260609.htm"},"events":[{"id":5808,"run_id":5091,"accession_number":"0001801170-26-000137","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"A federal court granted summary judgment in favor of Clover's subsidiary, setting aside an unfavorable 3.5 Star Rating and ordering CMS to recalculate. CMS subsequently increased the rating to 4.5 Stars for Contract H5141, which covers over 97% of Clover's members. This favorable litigation outcome and material improvement in Star Ratings—which directly impact Medicare Advantage payment rates and competitive positioning—would affect a reasonable investor's assessment of the company's financial prospects and operational performance, but does not fit neatly into the more specific event categories (it is neither a settlement of adverse litigation nor a routine administrative matter).","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5740,"accession_number":"0001801170-26-000137","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"A federal court granted summary judgment in favor of Clover's subsidiary, setting aside an unfavorable 3.5 Star Rating and ordering CMS to recalculate. CMS subsequently increased the rating to 4.5 Stars for Contract H5141, which covers over 97% of Clover's members. This favorable litigation outcome and material improvement in Star Ratings—which directly impact Medicare Advantage payment rates and competitive positioning—would affect a reasonable investor's assessment of the company's financial prospects and operational performance, but does not fit neatly into the more specific event categories (it is neither a settlement of adverse litigation nor a routine administrative matter).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T12:32:27.726975+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5740,"accession_number":"0001801170-26-000137","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"A federal court granted summary judgment in favor of Clover's subsidiary, setting aside an unfavorable 3.5 Star Rating and ordering CMS to recalculate. CMS subsequently increased the rating to 4.5 Stars for Contract H5141, which covers over 97% of Clover's members. This favorable litigation outcome and material improvement in Star Ratings—which directly impact Medicare Advantage payment rates and competitive positioning—would affect a reasonable investor's assessment of the company's financial prospects and operational performance, but does not fit neatly into the more specific event categories (it is neither a settlement of adverse litigation nor a routine administrative matter).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T12:32:27.726975+00:00","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","filing_date":"2026-06-10"}]}